The role of cell-free DNA in fibrinolysis for intraventricular hemorrhage

被引:6
|
作者
Xie, Fangke [1 ]
Tan, Qiang [2 ]
Yu, Anyong [1 ]
Guo, Peiwen [2 ]
Wang, Ling [2 ]
Zeng, Zongwei [2 ]
Liang, Liang [2 ]
Xian, Jishu [2 ]
Feng, Hua [2 ]
Chen, Zhi [2 ]
机构
[1] Zunyi Med Univ, Affiliated Hosp, Dept Emergency, Zunyi, Peoples R China
[2] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing, Peoples R China
基金
中国国家自然科学基金;
关键词
intraventricular hemorrhage; tissue plasminogen activator; neutrophil extracellular traps; cell-free DNA; fibrinolysis; vascular disorders; NEUTROPHIL EXTRACELLULAR TRAPS; TISSUE-PLASMINOGEN ACTIVATOR; CITRULLINATED HISTONE H3; CANINE MODEL; BLOOD-CLOT; UROKINASE; HEMATOMA; LYSIS; THERAPY;
D O I
10.3171/2020.7.JNS201429
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
OBJECTIVE Tissue plasminogen activator (tPA) fibrinolysis did not improve functional outcomes of patients with intraventricular hemorrhage (IVH), largely because of the unsatisfactory clot clearance. The presence of neutrophil extracellular traps (NETs) within the clot has been confirmed to impair tPA fibrinolysis, but the mechanism has been unclear. The authors hypothesized that cell-free DNA (cfDNA), the main framework of NETs, might be the important reason for the fibrinolysis resistance, and they validated the hypothesis, hoping to provide a new target to promote intraventricular fibrinolysis. METHODS First, cfDNA was detected in IVH clots by immunofluorescence staining in a rat model of IVH. Second, after blood (with or without exogenous cfDNA) intraventricular injection, IVH rats were given intraventricular infusion of 2 mu l of saline, tPA, or tPA + DNase1 randomly. Then, the ventricular volume, animal behavior, and reactive astrocyte proliferation were assessed. Third, the IVH clots were collected for fibrinolysis assay in vitro. Finally, the effects of exogenous cfDNA in IVH were evaluated. RESULTS The presence of cfDNA in clots was observed as early as 1 hour after IVH. Compared with the whole-blood model, blood + cfDNA caused more severe ventricular dilation (day 7: blood 32.47 +/- 2.096 mm(3) vs blood + DNA 40.09 +/- 2.787 mm(3), p < 0.05), increased fibrinolysis resistance to tPA (day 7: tPA + DNA 26.04 +/- 1.318 mm(3) vs tPA 22.15 +/- 1.706 mm(3), p < 0.05), and further deteriorated the functional defects in rats (blood vs blood + DNA, p < 0.05). Degradation of cfDNA by DNase1 further enhanced the fibrinolysis effects on relieving the ventricular dilation (day 7: tPA + DNase1 11.67 +/- 2.023 mm(3) vs tPA, p < 0.05), improving the functional outcome (tPA vs tPA + DNase1, p < 0.05) and reducing periventricular astrocyte proliferation. CONCLUSIONS cfDNA impaired tPA fibrinolysis for IVH, and degradation of cfDNA may be a new target to improve this condition.
引用
收藏
页码:1105 / 1112
页数:8
相关论文
共 50 条
  • [41] The role of circulating cell-free DNA as an inflammatory mediator after stroke
    Stefan Roth
    Saskia R. Wernsdorf
    Arthur Liesz
    Seminars in Immunopathology, 2023, 45 : 411 - 425
  • [42] The Current Role of Circulating Cell-Free DNA in the Management of Hepatocellular Carcinoma
    Papatheodoridi, Alkistis
    Lekakis, Vasileios
    Chatzigeorgiou, Antonios
    Papatheodoridis, George
    CANCERS, 2025, 17 (06)
  • [43] The Role of Cell-Free Plasma DNA in Critically Ill Patients with Sepsis
    Clementi, Anna
    Virzi, Grazia Maria
    Brocca, Alessandra
    Pastori, Silvia
    de Cal, Massimo
    Marcante, Stefano
    Granata, Antonio
    Ronco, Claudio
    BLOOD PURIFICATION, 2016, 41 (1-3) : 34 - 40
  • [44] The emerging role of cell-free DNA as a molecular marker for duodenal adenocarcinoma
    Lai, Hon-Fan
    Wang, Shin-E
    Chen, Shih-Chin
    Shyr, Bor-Shiuan
    Shyr, Yi-Ming
    Shyr, Bor-Uei
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2024, 87 (04) : 422 - 427
  • [45] The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer
    Ellinger, Joerg
    Mueller, Stefan C.
    Stadler, Thomas C.
    Jung, Andreas
    von Ruecker, Alexander
    Bastian, Patrick J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011, 29 (02) : 124 - 129
  • [46] The role of cell-free DNA size distribution in the management of prostate cancer
    Boddy, Jane L.
    Gal, Shira
    Malone, Peter R.
    Shaida, Nadeem
    Wainscoat, James S.
    Harris, Adrian L.
    ONCOLOGY RESEARCH, 2006, 16 (01) : 35 - 41
  • [47] Clinical relevance of cell-free DNA during venovenous extracorporeal membrane oxygenation
    Lingel, Maximilian P.
    Haus, Moritz
    Paschke, Lukas
    Foltan, Maik
    Lubnow, Matthias
    Gruber, Michael
    Krenkel, Lars
    Lehle, Karla
    ARTIFICIAL ORGANS, 2023, 47 (11) : 1720 - 1731
  • [48] Increased cell-free DNA in CSF and serum of hip fracture patients with delirium
    Bratseth, Vibeke
    Watne, Leiv Otto
    Neerland, Bjorn Erik
    Halaas, Nathalie Bodd
    Pollmann, Christian Thomas
    Karabeg, Adi
    Odegaard, Olav Tobias
    Sydnes, Kristian
    Zetterberg, Henrik
    Seljeflot, Ingebjorg
    Helseth, Ragnhild
    BRAIN COMMUNICATIONS, 2024, 7 (01)
  • [49] Saliva-based cell-free DNA and cell-free mitochondrial DNA in head and neck cancers have promising screening and early detection role
    Sayal, Lana
    Hamadah, Omar
    Almasri, Aroub
    Idrees, Majdy
    Thomson, Peter
    Kujan, Omar
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2023, 52 (01) : 29 - 36
  • [50] Cell-Free DNA in the Investigation of Miscarriage
    Colley, Emily
    Devall, Adam J.
    Williams, Helen
    Hamilton, Susan
    Smith, Paul
    Morgan, Neil V.
    Quenby, Siobhan
    Coomarasamy, Arri
    Allen, Stephanie
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 11